By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...

By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results ...

Patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20% reduction in the risk of developing metastasis ...

Johnson & Johnson (J&J) has announced results from the final analysis of the phase 3 PROTEUS study showing that Erleada ...

According to data from two phase III trials presented at this year's American Society of Clinical Oncology Genitourinary Cancers Symposium, patients with high-risk prostate cancer had a significantly ...

A dose reduction of Erleada may result in fewer skin-related side effects for men with advanced prostate cancer — but only for those with a smaller body size, research showed. A dose reduction of ...

A state-of-the-art laser prostate reduction operation is now being successfully delivered in the county as a day case procedure. HOLEP, or Holmium Laser Enucleation of the Prostate, is a minimally ...

A European study has demonstrated a sustained long-term reduction in prostate cancer mortality through prostate-specific antigen (PSA) screening. However, the findings also highlight the issue of ...

To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10373/251904_9ea3c480f4166aa2_001full.jpg "My family has a history of ...

The most common surgery for prostate cancer is a radical prostatectomy. This surgery involves taking out the entire prostate gland, some lymph nodes and other nearby tissue, like the seminal vesicles ...

Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the ris ...